FRACTYL HEALTH, INC. Material Event

Fractyl Health, Inc. recently received a significant warning from Nasdaq, the stock exchange where its shares trade. This summary explains the event, its implications, and what investors should monitor.

---

Event Description

Fractyl Health received a formal warning from Nasdaq because its stock price fell below the exchange's minimum bid requirement. Specifically, the company's shares traded below $1.00 for 30 consecutive business days.

Nasdaq maintains listing rules to ensure companies are stable and reputable for investors. One such rule, Listing Rule 5450(a)(1), requires a company's stock to maintain a minimum bid price of $1.00 per share. Fractyl's stock consistently traded below this threshold for a month, triggering the warning. Such a situation often indicates a company faces significant challenges, such as slower-than-expected progress in clinical trials, competitive pressures, or broader financial concerns that erode investor confidence. While this 8-K filing specifically addresses the Nasdaq notice, investors should consult Fractyl's recent quarterly (10-Q) and annual (10-K) reports for a deeper understanding of the underlying business performance and financial health that may have contributed to the stock price decline.

---

Event Date and Timeline

Fractyl Health received this official notice on March 13, 2026.

The company has 180 calendar days, until September 9, 2026, to regain compliance. To do so, its stock price must close at $1.00 or more for at least 10 consecutive business days at any point during this period. The notice does not immediately impact the stock's listing.

If Fractyl does not regain compliance within the initial 180 days, it may qualify for an additional 180-day period. To secure this extension, the company would need to apply for a transfer to the Nasdaq Capital Market (a smaller market within Nasdaq) and demonstrate a clear plan to resolve the issue, potentially through a reverse stock split. Failure to regain compliance, or a Nasdaq determination that the company cannot meet the requirements, could lead to the stock's delisting from Nasdaq entirely.

---

Impact Assessment

This Nasdaq warning represents a serious challenge for Fractyl Health. If the company fails to raise its stock price above $1.00 and maintain that level, its shares could eventually be delisted from the Nasdaq exchange. Delisting significantly hinders investors' ability to buy and sell the stock, damages the company's reputation, and impairs its future ability to raise capital. It signals to the market that the company faces significant difficulties.

This situation affects several key stakeholders:

• Investors: This is generally negative news. It introduces considerable uncertainty and could intensify selling pressure on the stock. Should the stock be delisted, trading becomes much more difficult, potentially trapping investors or forcing them to sell at lower prices on less regulated, "over-the-counter" markets.
• Customers/Patients: In the short term, this news likely does not directly affect patients or customers. The company's operations and product development typically remain separate from its stock price performance.
• Employees: A struggling stock price and the threat of delisting can create anxiety among employees regarding the company's financial health and job security. It can also impede the company's ability to attract new talent.
• The Company Itself (Fractyl Health): This presents a major challenge. Fractyl must now dedicate resources to strategies for boosting its stock price, which could include a reverse stock split or significant business changes to reassure investors. The situation also negatively impacts its reputation and its capacity to attract new investors or raise capital.

---

Financial Impact

The primary financial impact stems from the potential delisting. Delisting would significantly reduce the liquidity and marketability of Fractyl's common stock, making it much harder for investors to buy or sell shares. This typically leads to a substantial decrease in the stock's value.

Furthermore, non-compliance and potential delisting can negatively affect the company's ability to raise capital through equity offerings. Institutional investors often have mandates against investing in non-compliant or delisted companies, which could constrain Fractyl's financial flexibility and its ability to fund operations, clinical trials, and strategic initiatives.

Fractyl may consider a reverse stock split to regain compliance. While a reverse stock split addresses the bid price requirement, it does not fundamentally change the company's market capitalization or underlying financial health. Moreover, the market sometimes perceives reverse stock splits negatively, which can lead to further stock price declines.

The notice itself does not impose immediate financial penalties or direct costs beyond potential administrative fees associated with compliance efforts.

---

Key Takeaways for Investors

For investors, understanding the implications of this Nasdaq warning is crucial:

• Overall Sentiment: This is generally negative news. It signals financial distress or a lack of investor confidence and introduces significant risk regarding the company's future on a major exchange.
• Key Considerations: If you own Fractyl stock, be acutely aware of the delisting risk. The company might implement a reverse stock split, combining existing shares into fewer, more valuable shares (e.g., 10 shares become 1 share, and the price increases from $0.50 to $5.00). While this addresses the price issue, it does not alter the company's underlying value or business fundamentals. A reverse split can sometimes precede further price declines if the market does not perceive a fundamental improvement in the company's operations. If the stock is delisted, trading will become significantly more difficult, and its value could drop substantially.
• Company's Stated Intentions: Fractyl has stated its intention to "actively monitor" its price and "consider available options" to regain compliance. These options could include a reverse stock split or pursuing a transfer to the Nasdaq Capital Market. However, the company has not yet announced a specific, concrete plan of action beyond these general statements.
• Critical Factors to Watch:
  • Stock Price Performance: Monitor the stock price over the next 180 days (until September 9, 2026) to see if it closes above $1.00 for 10 consecutive days.
  • Company Announcements: Watch for specific announcements from Fractyl regarding its strategy to regain compliance, particularly details on a reverse stock split ratio or a formal plan to transfer to the Nasdaq Capital Market.
  • Business Fundamentals: Crucially, look beyond the stock price. Review upcoming financial reports (e.g., the next 10-Q filing) for signs of improving business fundamentals, including:
    • Cash Position and Burn Rate: Assess available cash and the rate at which it is being spent to understand the company's financial runway.
    • Revenue Trends: Analyze revenue growth and its sources.
    • Clinical Trial Progress: Look for updates on key clinical trials (e.g., for Revita or Rejuva), data readouts, or regulatory milestones that could drive long-term value.
    • Strategic Initiatives: Identify any new partnerships, market expansion plans, or cost-saving measures being implemented.

Understanding these underlying factors is essential, as a technical fix like a reverse split will not resolve fundamental business challenges.